Clinical Trial Update: iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab [Phase 2]

View source ↗

Summary

A Phase 2 trial update discussing how iRECIST criteria relate to disease control rate in MMR/MSI metastatic colorectal cancer patients treated with nivolumab pl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Metastatic Cancer Colorectal | Phase 2 | Status: ACTIVE_NOT_RECRUITING